(TGTX) TG Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 5.808m USD | Total Return: 2.5% in 12m
Avg Turnover: 62.3M
Qual. Beats: -2
Rev. Trend: 80.8%
Qual. Beats: 0
Warnings
Earnings expected to drop: P/E 13.3 → Forward 29.2
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Below Avwap Earnings
Tailwinds
Confidence
TG Therapeutics Inc (TGTX) is a commercial-stage biopharmaceutical firm specializing in therapies for B-cell mediated diseases, primarily multiple sclerosis (MS) and B-cell malignancies. Its lead commercial product, BRIUMVI, is an anti-CD20 monoclonal antibody approved for treating various relapsing forms of MS in adults. The companys development model relies on a mix of internal research and strategic licensing agreements with international partners to expand its pipeline of kinase inhibitors and bispecific antibodies.
The biotechnology sector often requires high research and development (R&D) expenditure and navigating rigorous FDA regulatory pathways before achieving commercial revenue. TGTX’s business model centers on the glycoengineering of antibodies, a process designed to enhance the potency of biologics by modifying their carbohydrate structures to improve immune system interaction. Beyond its primary MS focus, the company is investigating BTK inhibitors and CD47/CD19 bispecific antibodies to address unmet needs in oncology.
For a deeper look into the companys valuation metrics and financial health, consider reviewing the data available on ValueRay. TG Therapeutics operates out of Morrisville, North Carolina, and maintains a global presence through its distribution and licensing networks.
- Briumvi adoption rates in the competitive multiple sclerosis market drive revenue growth
- Expansion into subcutaneous administration improves long-term product positioning and patient convenience
- International commercialization partnerships determine royalty income and global market penetration
- Research and development expenses for bispecific antibodies impact overall cash burn rates
- Medicare pricing negotiations and reimbursement policies influence net product realized price
| Net Income: 461.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 8.38 > 1.0 |
| NWC/Revenue: 128.5% < 20% (prev 125.3%; Δ 3.15% < -1%) |
| CFO/TA -0.01 > 3% & CFO -14.0m > Net Income 461.9m |
| Net Debt (247.5m) to EBITDA (156.9m): 1.58 < 3 |
| Current Ratio: 5.81 > 1.5 & < 3 |
| Outstanding Shares: last quarter (160.1m) vs 12m ago -1.66% < -2% |
| Gross Margin: 83.04% > 18% (prev 0.87%; Δ 8.22k% > 0.5%) |
| Asset Turnover: 64.09% > 50% (prev 58.84%; Δ 5.25% > 0%) |
| Interest Coverage Ratio: 5.67 > 6 (EBITDA TTM 156.9m / Interest Expense TTM 27.6m) |
| A: 0.59 (Total Current Assets 1.09b - Total Current Liabilities 187.1m) / Total Assets 1.53b |
| B: -0.69 (Retained Earnings -1.06b / Total Assets 1.53b) |
| C: 0.14 (EBIT TTM 156.6m / Avg Total Assets 1.09b) |
| D: -1.12 (Book Value of Equity -1.06b / Total Liabilities 945.7m) |
| Altman-Z'' = 1.38 = BB |
| DSRI: 1.14 (Receivables 392.0m/190.1m, Revenue 700.3m/386.4m) |
| GMI: 1.05 (GM 83.04% / 87.43%) |
| AQI: 35.61 (AQ_t 0.28 / AQ_t-1 0.01) |
| SGI: 1.81 (Revenue 700.3m / 386.4m) |
| TATA: 0.31 (NI 461.9m - CFO -14.0m) / TA 1.53b) |
| Beneish M = 18.56 (Cap -4..+1) = D |
As of June 03, 2026, the stock is trading at USD 36.64 with a total of 1,042,602 shares traded.
Over the past week, the price has changed by -7.78%,
over one month by +2.62%,
over three months by +24.63% and
over the past year by +2.49%.
TG Therapeutics has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy TGTX.
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 48 | 31% |
P/E Trailing = 13.2657
P/E Forward = 29.1545
P/S = 8.293
P/B = 9.9587
P/EG = 1.6144
Revenue TTM = 700.3m USD
EBIT TTM = 156.6m USD
EBITDA TTM = 156.9m USD
Long Term Debt = 745.1m USD (from longTermDebt, last quarter)
Short Term Debt = 1.82m USD (from shortTermDebt, last quarter)
Debt = 762.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.42m
Net Debt = 247.5m USD (calculated: Debt 762.0m - CCE 514.4m)
Enterprise Value = 6.06b USD (5.81b + Debt 762.0m - CCE 514.4m)
Interest Coverage Ratio = 5.67 (Ebit TTM 156.6m / Interest Expense TTM 27.6m)
EV/FCF = -426.7x (Enterprise Value 6.06b / FCF TTM -14.2m)
FCF Yield = -0.23% (FCF TTM -14.2m / Enterprise Value 6.06b)
FCF Margin = -2.03% (FCF TTM -14.2m / Revenue TTM 700.3m)
Net Margin = 65.95% (Net Income TTM 461.9m / Revenue TTM 700.3m)
Gross Margin = 83.04% ((Revenue TTM 700.3m - Cost of Revenue TTM 118.7m) / Revenue TTM)
Gross Margin QoQ = 83.65% (prev 80.19%)
Tobins Q-Ratio = 3.96 (Enterprise Value 6.06b / Total Assets 1.53b)
Interest Expense / Debt = 3.63% (Interest Expense 27.6m / Debt 762.0m)
Taxrate = 2.88% (586k / 20.4m)
NOPAT = 152.1m (EBIT 156.6m * (1 - 2.88%))
Current Ratio = 5.81 (Total Current Assets 1.09b / Total Current Liabilities 187.1m)
Debt / Equity = 1.31 (Debt 762.0m / totalStockholderEquity, last quarter 583.1m)
Debt / EBITDA = 1.58 (Net Debt 247.5m / EBITDA 156.9m)
Debt / FCF = -17.44 (negative FCF - burning cash) (Net Debt 247.5m / FCF TTM -14.2m)
Total Stockholder Equity = 528.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 42.27% (Net Income 461.9m / Total Assets 1.53b)
RoE = 29.03% (Net Income TTM 461.9m / Total Stockholder Equity 1.59b)
RoCE = 6.70% (EBIT 156.6m / Capital Employed (Equity 1.59b + L.T.Debt 745.1m))
RoIC = 18.34% (NOPAT 152.1m / Invested Capital 829.1m)
WACC = 8.42% (E(5.81b)/V(6.57b) * Re(9.06%) + D(762.0m)/V(6.57b) * Rd(3.63%) * (1-Tc(0.03)))
Discount Rate = 9.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 33.33 | Cagr: 5.11%
[DCF] Fair Price = unknown (Cash Flow -14.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.06 | # QB: -2
Revenue Correlation: 80.76 | Revenue CAGR: 119.6% | SUE: 0.71 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.46 | Chg30d=+38.69% | Revisions=-20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.43 | Chg30d=+35.75% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=1.54 | Chg30d=+30.58% | Revisions=+33% | GrowthEPS=-44.6% | GrowthRev=+52.6%
EPS next Year (2027-12-31): EPS=2.90 | Chg30d=+21.98% | Revisions=-33% | GrowthEPS=+88.8% | GrowthRev=+30.3%
[Analyst] Revisions Ratio: +33%